#AAN26: Roche’s Multiple Sclerosis Pill Delays Relapse, but Liver Toxicity Could Need Monitoring

Why It Matters

The extended relapse‑free period could shift treatment paradigms toward oral BTK inhibitors, while safety monitoring requirements may affect prescribing practices and market adoption.

Key Takeaways

• Fenebrutinib doubled relapse‑free interval versus Sanofi’s Aubagio.
• Phase 3 trial showed 68% of patients remained relapse‑free at 24 months.
• Liver enzyme elevations observed in 8% of participants, prompting monitoring.
• BTK inhibition offers oral alternative to injectable MS therapies.
• Roche aims for U.S. FDA filing by Q4 2026.

Pulse Analysis

Multiple sclerosis treatment has long been dominated by injectable disease‑modifying therapies and a handful of oral options such as Sanofi’s Aubagio. The emergence of BTK inhibitors marks a new class that targets B‑cell signaling pathways implicated in neuroinflammation. Roche’s fenebrutinib, already in late‑stage development, leverages this mechanism to deliver an all‑oral regimen, potentially simplifying adherence for patients who struggle with injection schedules.

The Phase 3 trial data released this week reveal that fenebrutinib more than doubled the relapse‑free interval versus Aubagio, with 68% of participants staying relapse‑free after 24 months. While the efficacy signal is compelling, the safety profile shows liver enzyme elevations in roughly 8% of patients, a finding that will likely trigger routine hepatic monitoring in clinical practice. Compared with existing oral agents, fenebrutinib’s potency and safety balance could position it as a preferred option for patients with active disease who seek a non‑injectable solution.

From a market perspective, Roche’s move could reshape the competitive landscape. An FDA filing slated for Q4 2026 would place fenebrutinib alongside other BTK candidates from companies like Eli Lilly and Novartis, intensifying the race for the first oral BTK inhibitor approval. If approved, the drug could capture a sizable share of the $15 billion global MS market, especially among patients dissatisfied with current therapies. Moreover, the requirement for liver monitoring may influence payer coverage decisions and physician prescribing habits, underscoring the importance of post‑marketing safety data.